Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Soumerai, J. D.
369  Ergebnisse:
?
1

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) With R..:

Shah, Nirav N. ; Siddiqi, Tanya ; Maloney, David G....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S353-S354 , 2024
Link: https://doi.org/10.1016/..
 
?
2

IgG Testing, Immunoglobulin Replacement Therapy, and Infect..:

Soumerai, Jacob D. ; Yousif, Zaid ; Gift, Thais...
Blood Advances.  , 2024
Link: https://doi.org/10.1182/..
 
?
3

Nivolumab for mismatch-repair-deficient or hypermutated gyn..:

Friedman, Claire F. ; Manning-Geist, Beryl L. ; Zhou, Qin...
Nature Medicine.  30 (2024)  5 - p. 1330-1338 , 2024
Link: https://doi.org/10.1038/..
 
?
4

Online group-based internal family systems treatment for po..:

Comeau, Alexandra ; Smith, Lia J. ; Smith, Lydia...
Psychological Trauma: Theory, Research, Practice, and Policy.  , 2024
Link: https://doi.org/10.1037/..
 
?
5

Safety and efficacy of zandelisib plus zanubrutinib in prev..:

Soumerai, Jacob D. ; Diefenbach, Catherine S. ; Jagadeesh, Deepa...
British Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
6

CTIM-38. NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECOND..:

Karschnia, Philipp ; Arrillaga-Romany, Isabel ; Eichler, April...
Neuro-Oncology.  25 (2023)  Supplement_5 - p. v71-v71 , 2023
Link: https://doi.org/10.1093/..
 
?
7

LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBR..:

Soumerai, J. D. ; Dogan, A. ; Seshan, V....
Hematological Oncology.  41 (2023)  S2 - p. 233-235 , 2023
Link: https://doi.org/10.1002/..
 
?
8

CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S320-S321 , 2023
Link: https://doi.org/10.1016/..
 
?
9

REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRA..:

Soumerai, J. ; Wang, L. ; Gu, F...
Hematological Oncology.  41 (2023)  S2 - p. 733-734 , 2023
Link: https://doi.org/10.1002/..
 
?
10

Lisocabtagene maraleucel in chronic lymphocytic leukaemia a..:

Siddiqi, Tanya ; Maloney, David G ; Kenderian, Saad S...
The Lancet.  402 (2023)  10402 - p. 641-654 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Metabolic parameters predict survival and toxicity in chime..:

Ababneh, Hazim S. ; Ng, Andrea K. ; Abramson, Jeremy S....
Hematological Oncology.  42 (2023)  1 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
12

P06.11.B NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECOND..:

Karschnia, P ; Arrillaga-Romany, I C ; Eichler, A...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii47-ii48 , 2023
Link: https://doi.org/10.1093/..
 
?
13

Ayres Sensory Integration Therapy for a Child With Rett Syn..:

Rocco, Karen ; Drobnyk, Wendy` ; Bruce, Susan.
Clinical Medicine Insights: Pediatrics.  17 (2023)  - p. , 2023
Link: https://doi.org/10.1177/..
 
?
14

Oral Abstract: CLL-094 Lisocabtagene Maraleucel (liso-cel) ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S146 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Neurotoxicity and management of primary and secondary centr..:

Karschnia, Philipp ; Arrillaga-Romany, Isabel C ; Eichler, April...
Neuro-Oncology.  25 (2023)  12 - p. 2239-2249 , 2023
Link: https://doi.org/10.1093/..
 
1-15